Lyfebulb and Veloxis Pharmaceuticals Seek Applicants for the Global 2022 Innovation Challenge in Organ Transplantation

NEW YORK and NORTH CAROLINA, July 26, 2022 — Lyfebulb, a patient-empowerment platform that connects patients with industry experts to support user-driven innovation, and Veloxis Pharmaceuticals, an Asahi Kasei, fully integrated specialty pharmaceutical company, invite entrepreneurs to apply to their “Transforming Organ Transplantation Through Innovation” Challenge.

The Lyfebulb-Veloxis Innovation Challenge is seeking a wide range of solutions to improve lived-experience and outcomes for individuals affected by transplant:

• Treatments, methods and/or procedures
• Diagnostics, patient monitoring and/or services
• System-wide improvements to care
• Advancements in health equity
• Improvements to quality of life

“Transplantation is a complex medical, surgical, and mental process that not only gives the recipient a new take on life, but also brings new challenges that need to be addressed personally and understood by society. Living life post-transplant should not mean hiding from activities you loved before your diagnosis, nor should it lead to the need for additional medical procedures. Through this Innovation Challenge, we encourage entrepreneurial thinkers globally to bring us concepts, services and products that will allow patients, care partners and donors to thrive,” said Dr. Karin Hehenberger, CEO and Founder of Lyfebulb.

Selected applicants will receive an invitation to pitch their business ventures to an expert panel of judges composed of healthcare industry, medical and patient leaders over the course of a two-day summit at Veloxis’ headquarters in Cary, N.C. on October 13-14, 2022. Prizes will be awarded to two finalists to further grow their companies. The Innovation Award will be presented to a for-profit company and includes a $25,000 monetary grant. The Impact Award will be presented to a not-for-profit company and includes a $15,000 monetary grant. Additionally, Veloxis Pharmaceuticals may consider possible partnerships or investment opportunities with finalists beyond the challenge.

In addition to the pitch competition, finalists will have the opportunity to engage with representatives from the patient community, industry, Lyfebulb and Veloxis through workshops, learning hubs and informal networking.

“At Veloxis, we are committed to improving the lives and outcomes of transplant patients across the globe,” says Mark Hensley, CEO of Veloxis. “We are excited to partner with Lyfebulb in hosting the Innovation Challenge and are looking forward to seeing what talented entrepreneurs come up with as solutions to problems facing this unique population.”

The competition is free to enter and open to U.S. and international applicants. Official eligibility criteria and terms and conditions can be found on Lyfebulb.com: https://lyfebulb.com/innovation-challenges/challenges/veloxis-pharmaceuticals-innovation-challenge-the-future-of-transplantation.